Lab
Central Clinical Labs Incorporated
Central Clinical Labs Incorporated was paid $6.10M by Medicaid between Jan 2018 and Nov 2024, across 170 billing codes. Its largest line is P9604, Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge — 17% of everything it billed.
33Billing provider infoCENTRAL CLINICAL LABS INCORPORATED
PHOENIX, AZ 85040
PHOENIX, AZ 85040
33aNPI1598106163assigned 07/11/2013
33bProvider typeClinical Medical Laboratory
28Total paid$6.10M
24GClaims1,372,807
24DCodes billed170
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Arizona
Rank by total paid#12 of 67
Median peer was paid$89K
This provider vs. median68×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 100,586 | $265K | |
| 2019 | 124,469 | $347K | |
| 2020 | 195,967 | $746K | |
| 2021 | 215,892 | $1.11M | |
| 2022 | 224,500 | $977K | |
| 2023 | 302,052 | $1.46M | |
| 2024incomplete | 209,341 | $1.20M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 17% | 138,443 | 96,201 | $1.06M |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 7.1% | 49,042 | 44,511 | $435K |
| 80053 | Comprehensive metabolic panel | 5.2% | 110,926 | 90,370 | $318K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.9% | 4,902 | 4,202 | $302K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.6% | 131,451 | 98,991 | $283K |
| 84443 | Thyroid stimulating hormone (TSH) | 4.3% | 63,954 | 58,177 | $260K |
| 80061 | Lipid panel | 4.2% | 63,077 | 57,646 | $255K |
| 80050 | General health panel | 3.6% | 17,226 | 16,240 | $218K |
| 86480 | 3.3% | 5,891 | 5,752 | $199K | |
| 36415 | Collection of venous blood by venipuncture | 3.2% | 151,835 | 117,223 | $195K |
| 83036 | Hemoglobin; glycosylated (A1C) | 3.1% | 62,961 | 57,475 | $188K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.0% | 4,168 | 2,666 | $186K |
158 more codes
| 82607 | 2.7% | 33,945 | $165K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.1% | 5,790 | $126K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.1% | 5,794 | $126K |
| 82746 | 2.0% | 24,011 | $121K | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | 1.8% | 17,656 | $110K |
| 84439 | 1.3% | 29,224 | $80K | |
| 80305 | 1.3% | 9,733 | $78K | |
| 86803 | 1.1% | 9,048 | $69K | |
| 84481 | 1.1% | 13,244 | $68K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.1% | 27,311 | $67K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,001 | $55K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 1,087 | $46K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 27,878 | $42K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 7,053 | $41K |
| 86141 | <1% | 7,780 | $39K | |
| 83880 | <1% | 6,387 | $38K | |
| 84153 | <1% | 8,303 | $37K | |
| 82728 | <1% | 10,553 | $34K | |
| 86769 | <1% | 1,098 | $33K | |
| 83550 | <1% | 14,809 | $33K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,751 | $33K |
| 87340 | <1% | 5,237 | $29K | |
| 87186 | <1% | 12,472 | $28K | |
| 87522 | Neg quan hep c or qual rna | <1% | 1,792 | $28K |
| 82140 | <1% | 4,599 | $28K | |
| 80202 | <1% | 3,949 | $27K | |
| 83540 | <1% | 15,878 | $27K | |
| 86704 | <1% | 4,082 | $27K | |
| 83735 | <1% | 17,022 | $26K | |
| 83970 | <1% | 3,973 | $25K | |
| 84154 | <1% | 4,660 | $23K | |
| 87077 | <1% | 16,778 | $22K | |
| 84403 | <1% | 2,922 | $22K | |
| 80164 | <1% | 5,630 | $19K | |
| 87088 | <1% | 8,050 | $18K | |
| 84402 | <1% | 2,257 | $18K | |
| 86592 | <1% | 6,248 | $17K | |
| 86696 | <1% | 1,251 | $16K | |
| 86708 | <1% | 2,669 | $16K | |
| 84270 | <1% | 2,306 | $15K | |
| 85651 | <1% | 8,921 | $14K | |
| 86695 | <1% | 1,481 | $13K | |
| 86706 | <1% | 2,393 | $12K | |
| 86709 | <1% | 2,230 | $12K | |
| 81003 | <1% | 15,224 | $12K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 180 | $11K |
| 82570 | <1% | 9,665 | $10K | |
| 84100 | <1% | 9,026 | $10K | |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | <1% | 21,623 | $9K |
| 87481 | <1% | 1,313 | $8K | |
| 85610 | <1% | 14,534 | $8K | |
| 84146 | <1% | 1,176 | $8K | |
| 81001 | <1% | 19,819 | $8K | |
| 87040 | <1% | 965 | $7K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 208 | $7K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 717 | $7K |
| 86705 | <1% | 1,385 | $7K | |
| 82043 | <1% | 3,579 | $7K | |
| 82274 | <1% | 2,498 | $6K | |
| 86317 | <1% | 569 | $6K | |
| 86780 | <1% | 767 | $6K | |
| 80076 | <1% | 6,132 | $6K | |
| 87902 | <1% | 124 | $6K | |
| 82977 | <1% | 1,111 | $6K | |
| 84550 | <1% | 6,105 | $6K | |
| 87505 | <1% | 245 | $5K | |
| 86140 | <1% | 2,080 | $5K | |
| 87653 | <1% | 1,292 | $5K | |
| 87500 | <1% | 1,275 | $5K | |
| 87640 | <1% | 1,292 | $5K | |
| 86038 | <1% | 1,364 | $5K | |
| 80069 | <1% | 3,973 | $4K | |
| 85027 | <1% | 1,971 | $4K | |
| 84436 | <1% | 4,515 | $4K | |
| 84480 | <1% | 3,592 | $4K | |
| 84703 | <1% | 669 | $3K | |
| 84425 | <1% | 274 | $3K | |
| 83013 | <1% | 96 | $3K | |
| 80177 | <1% | 1,349 | $3K | |
| 82044 | <1% | 4,580 | $3K | |
| 82150 | <1% | 1,128 | $3K | |
| 87070 | <1% | 733 | $3K | |
| 87324 | <1% | 886 | $3K | |
| 87449 | <1% | 836 | $3K | |
| 83690 | <1% | 939 | $2K | |
| 82550 | <1% | 783 | $2K | |
| 84702 | <1% | 197 | $2K | |
| 80178 | <1% | 914 | $2K | |
| 84156 | <1% | 3,436 | $2K | |
| 82040 | <1% | 2,027 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 62 | $2K |
| 87529 | <1% | 42 | $2K | |
| 82552 | <1% | 507 | $1K | |
| 87205 | <1% | 617 | $1K | |
| 83525 | <1% | 160 | $1K | |
| 86593 | <1% | 410 | $1K | |
| 83090 | <1% | 112 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 92 | $1K |
| 82670 | <1% | 168 | $1K | |
| 86635 | <1% | 237 | $1K | |
| 84466 | <1% | 521 | $946.20 | |
| 85730 | <1% | 837 | $935.66 | |
| 85270 | <1% | 1,005 | $931.57 | |
| 83001 | <1% | 159 | $901.86 | |
| 81025 | <1% | 183 | $870.11 | |
| 86431 | <1% | 408 | $832.73 | |
| 84134 | <1% | 105 | $750.44 | |
| 83695 | <1% | 67 | $723.84 | |
| 86694 | <1% | 68 | $714.42 | |
| 84520 | <1% | 652 | $696.41 | |
| 85018 | <1% | 518 | $690.99 | |
| 82784 | <1% | 176 | $687.41 | |
| 84132 | <1% | 377 | $566.14 | |
| 84145 | <1% | 48 | $553.76 | |
| 87517 | <1% | 25 | $514.08 | |
| 87535 | <1% | 33 | $505.08 | |
| 82533 | <1% | 89 | $482.01 | |
| 87538 | <1% | 32 | $480.54 | |
| 87536 | <1% | 13 | $417.38 | |
| 82330 | <1% | 81 | $414.22 | |
| 85385 | <1% | 33 | $375.96 | |
| 83721 | <1% | 581 | $374.08 | |
| 86376 | <1% | 103 | $291.16 | |
| 83002 | <1% | 58 | $289.31 | |
| 85045 | <1% | 478 | $263.84 | |
| 86430 | <1% | 255 | $258.24 | |
| 86787 | <1% | 12 | $243.27 | |
| 85379 | <1% | 59 | $180.98 | |
| 80162 | <1% | 38 | $175.00 | |
| 85044 | <1% | 605 | $170.49 | |
| 82378 | <1% | 29 | $158.67 | |
| 84482 | <1% | 13 | $125.30 | |
| 83516 | <1% | 14 | $107.60 | |
| 85014 | <1% | 72 | $104.27 | |
| 83520 | <1% | 13 | $103.62 | |
| 84165 | <1% | 56 | $102.99 | |
| 85652 | <1% | 191 | $101.40 | |
| 80185 | <1% | 17 | $100.16 | |
| 80197 | <1% | 83 | $85.16 | |
| 82553 | <1% | 45 | $76.98 | |
| 84144 | <1% | 15 | $74.01 | |
| 87631 | <1% | 17 | $68.46 | |
| 82947 | <1% | 47 | $56.94 | |
| 82105 | <1% | 14 | $52.19 | |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | <1% | 20 | $50.92 |
| 82610 | <1% | 13 | $42.88 | |
| 87046 | <1% | 77 | $37.76 | |
| 80074 | <1% | 12 | $37.05 | |
| 84155 | <1% | 94 | $30.45 | |
| 80299 | <1% | 20 | $29.70 | |
| 83615 | <1% | 64 | $26.68 | |
| 85048 | <1% | 91 | $26.54 | |
| 87230 | <1% | 18 | $21.93 | |
| 86800 | <1% | 31 | $14.14 | |
| 85004 | <1% | 95 | $5.74 | |
| 84630 | 0% | 14 | $0.00 | |
| 99199 | Unlisted special service, procedure or report | 0% | 24 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 284 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialAHMAD, AYAZ (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Health Care Imaging INC | Phoenix, AZ | $4.04M |
| Mobile X-Ray of Austin INC | Austin, TX | $85K |
| CCL Labs LLC | Bedford, TX | $50K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.